Dermatology prior authorization at Horizon Blue Cross Blue Shield of New Jersey
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Horizon Blue Cross Blue Shield of New Jersey dermatology PA at a glance
Horizon Blue Cross Blue Shield of New Jersey reviews dermatology PA submissions against its medical policy library, with rules drawn primarily from AAD (American Academy of Dermatology) + NPF (National Psoriasis Foundation) for psoriasis. Horizon Blue Cross Blue Shield of New Jersey-specific context: Only BCBS licensee in New Jersey; ~3.7M members. OMNIA Health Plans (tiered network) generate frequent appeals — tier-2 hospital usage carries higher cost share. NJ DOBI oversight; NJ has a strong external review program (IHCAP via Maximus).
Documentation packet — what to send
- Diagnosis with ICD-10
- Severity score (PASI, BSA, IGA for psoriasis; EASI, IGA for AD)
- DLQI quality-of-life score
- Prior therapies tried: topicals, phototherapy, oral systemics
- Reason for discontinuation of each prior therapy
Common denial patterns to pre-empt
Patterns observed in dermatology across payers, and where Horizon Blue Cross Blue Shield of New Jersey's book of business overlaps:
- Psoriasis: PASI / BSA / IGA severity thresholds not met (typically PASI ≥10 or BSA ≥10%)
- Atopic dermatitis: severity score (EASI ≥21) not documented
- Step therapy through topicals / phototherapy first
- Quality-of-life impact (DLQI ≥10) not documented
- Special sites (face, scalp, hands) not flagged
- Step therapy on biologics
Appeal angles when Horizon Blue Cross Blue Shield of New Jersey denies
- AAD-NPF guideline citation for psoriasis
- AAD Atopic Dermatitis guideline citation
- DLQI severity argument
- Special-site involvement (face, hands, genitals) supporting expedited biologic
Peer-to-peer prep
- Have photos / clinical findings ready
- Quote the AAD-NPF guideline by year and recommendation grade
- Document failed phototherapy explicitly (NB-UVB, sessions, response)
- For DLQI: state the score AND the specific functional impacts patient reports
Drug-specific PA criteria at Horizon Blue Cross Blue Shield of New Jersey
Deep dives on each drug's PA criteria at Horizon Blue Cross Blue Shield of New Jersey:
Frequently asked questions
What documentation does Horizon Blue Cross Blue Shield of New Jersey need for dermatology prior authorizations?
Horizon Blue Cross Blue Shield of New Jersey's PA packet for dermatology typically includes: Diagnosis with ICD-10; Severity score (PASI, BSA, IGA for psoriasis; EASI, IGA for AD); DLQI quality-of-life score; Prior therapies tried: topicals, phototherapy, oral systemics. AAD (American Academy of Dermatology) + NPF (National Psoriasis Foundation) for psoriasis citations strengthen the submission.
What's the turnaround at Horizon Blue Cross Blue Shield of New Jersey?
Horizon Blue Cross Blue Shield of New Jersey standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which dermatology drugs does Horizon Blue Cross Blue Shield of New Jersey most often PA-restrict?
Top targets in dermatology: adalimumab, ustekinumab, secukinumab, guselkumab, risankizumab. Each follows the per-drug step therapy + documentation requirements published in Horizon Blue Cross Blue Shield of New Jersey's medical policy library.
How do I prep a peer-to-peer with Horizon Blue Cross Blue Shield of New Jersey in dermatology?
Have photos / clinical findings ready Quote the AAD-NPF guideline by year and recommendation grade Have the policy URL and the patient's chart open before the call.
Generate a Dermatology PA packet
Open ApprovalHelp — generate a dermatology PA packet tailored to Horizon Blue Cross Blue Shield of New Jersey's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com